Image via Wikipedia
A new drug combination tested in mice may target the cells responsible for driving some pancreatic tumors. The combination of gemcitabine and the experimental drug tigatuzumab eliminated populations of cancer stem cells and reduced tumor growth in a mouse model of pancreatic cancer, researchers from the Johns Hopkins Sidney Kimmel Cancer Center reported at the AACR annual meeting.
The results provide a rationale for testing the promising combination in patients with this deadly disease, Dr. Rajesh Kumar NV and his colleagues concluded.
Cancer stem cells are thought to self renew while giving rise to tumors, and they may
Piece by missing piece, scientists at the Keck School of Medicine of USC are deciphering the powerful gene regulatory circuit that maintains and controls the potential of embryonic stem cells (ESCs) to form any type of cell in the body.
Recent findings by Provost Professor Andrew McMahon, director of the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at USC, and Qilong Ying, associate professor of cell and neurobiology, underscore the essential role of basic science in paving the way for future medical breakthroughs.
McMahon and Ying are in pursuit of the ways in which the intricate
What do former British Prime Minister Tony Blair and singer Will.i.am have in common? They both attended this year’s Milken Institute Global Conference, where USC Stem Cellresearchers offered a glimpse into the future of regenerative medicine (…)
During a well-attended panel session about regenerative medicine, Paula Cannon, associate professor at the Keck School of Medicine and principal investigator with USC Stem Cell, talked about genetically modifying hematopoietic or blood-forming stem cells to cure HIV/AIDS (…)
She also emphasized the recent progress made in the field of stem cell biology as a whole (…)
One in 10 adults in the U.S. — more than 20 million people — are suffering from some degree of chronic kidney disease. Kidney transplants offer a hope for cure, but thousands of patients die each year due to a shortage of donor organs. Even patients who are lucky enough to receive transplants run the risk of their immune systems rejecting the donor kidneys, and they have to take immunosuppressive drugs with serious side effects for the rest of their lives.
Vito Campese, professor and chair of the Keck School of Medicine of USC’s nephrology division, underscores the need to